Insulin: Potential negative consequences of early routine use in patients with type 2 diabetes

Diabetes Care

Volumn 34, Issue SUPPL. 2, 2011, Pages

  Lebovitz, Harold E ^a  

^a SUNY Downstate Medical Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHLORPROPAMIDE; GLIBENCLAMIDE; GLUCAGON LIKE PEPTIDE 1 RECEPTOR; GLUCOSE; HEMOGLOBIN A1C; INSULIN; INSULIN RECEPTOR SUBSTRATE; METFORMIN; MITOGEN ACTIVATED PROTEIN KINASE; ORAL ANTIDIABETIC AGENT; PHOSPHATIDYLINOSITOL 3 KINASE; PLACEBO; ROSIGLITAZONE; SULFONYLUREA; TOLBUTAMIDE;

ANGIOPLASTY; ARTICLE; CANCER RISK; CARDIOVASCULAR RISK; COMBINATION CHEMOTHERAPY; DIABETIC ANGIOPATHY; DRUG DOSE INCREASE; DRUG FORMULATION; ENDOCRINE DISEASE; GLUCONEOGENESIS; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HORMONE ACTION; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN HYPOGLYCEMIA; INSULIN METABOLISM; INSULIN RELEASE; INSULIN RESISTANCE; INSULIN TREATMENT; ISCHEMIC HEART DISEASE; LONG TERM CARE; MITOGENESIS; MONOTHERAPY; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; PANCREAS CARCINOMA; PANCREAS ISLET BETA CELL; PSEUDOACROMEGALY; SIDE EFFECT; WEIGHT GAIN; BIOLOGICAL MODEL; METABOLISM;

DIABETES MELLITUS, TYPE 2; HUMANS; INSULIN; MODELS, BIOLOGICAL;

EID: 79959803383     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dc11-s225     Document Type: Article

References (45)

1. Marchetti P, Dotta F, Lauro D, Purrello F. An overview of pancreatic beta-cell defects in human type 2 diabetes: implications for treatment. Regul Pept 2008;146:4-11
2. Ferrannini E, Cobelli C. The kinetics of insulin in man. II. Role of the liver. Diabetes Metab Rev 1987;3:365-397 (Pubitemid 17050763)
3. Kido Y, Nakae J, Accili D. Clinical review 125: The insulin receptor and its cellular targets. J Clin Endocrinol Metab 2001;86: 972-979 (Pubitemid 32322967)
4. Savage DB, Petersen KF, Shulman GI. Disordered lipid metabolism and the pathogenesis of insulin resistance. Physiol Rev 2007;87:507-520 (Pubitemid 47084679)
5. Flier JS, Moller DE, Moses AC, et al. Insulin- mediated pseudoacromegaly: clinical and biochemical characterization of a syndrome of selective insulin resistance. J Clin Endocrinol Metab 1993;76:1533-1541 (Pubitemid 23164374)
6. Kausch C, Bergemann C, Hamann A, Matthaei S. Insulin-mediated pseudoacromegaly in a patient with severe insulin resistance: association of defective insulin-stimulated glucose transport with impaired phosphatidylinositol 3-kinase activity in fibroblasts. Exp Clin Endocrinol Diabetes 1999;107:148-154 (Pubitemid 29179282)
7. Yaqub A, Yaqub N. Insulin-mediated pseudoacromegaly: a case report and review of the literature. W V Med J 2008; 104:12-15
8. Dib K, Whitehead JP, Humphreys PJ, et al. Impaired activation of phosphoinositide 3-kinase by insulin in fibroblasts from patients with severe insulin resistance and pseudoacromegaly: a disorder characterized by selective postreceptor insulin resistance. J Clin Invest 1998;101:1111-1120 (Pubitemid 28125290)
9. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998;352:837-853
10. Turner RC, Cull CA, Frighi V, Holman RR; UK Prospective Diabetes Study (UKPDS) Group. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement formultiple therapies (UKPDS 49). JAMA 1999;281:2005-2012 (Pubitemid 29254858)
11. Holman RR, Farmer AJ, Davies MJ, et al. Three-year efficacy of complex insulin regimens in type 2 diabetes.NEngl J Med 2009; 361:1736-1747
12. University Group Diabetes Program. A study of the effects of hypoglycemic agents on vascular complications in patients with adult-onset diabetes. Diabetes 1970;19 (Suppl. 2):747-830
13. Knatterud GL, Klimt CR, Levin ME, Jacobson ME, Goldner MG; UGDP Group. Effects of hypoglycemic agents on vascular complications in patients with adult-onset diabetes. VII. Mortality and selected nonfatal events with insulin treatment. JAMA 1978; 240:37-42 (Pubitemid 8395565)
14. Bonds DE, Miller ME, Bergenstal RM, et al. The association between symptomatic, severe hypoglycaemia and mortality in type 2 diabetes: retrospective epidemiological analysis of the ACCORD study. BMJ 2010;340:b4909
15. Skyler JS, Bergenstal R, Bonow RO, et al. Intensive glycemic control and the prevention of cardiovascular events: implications of the ACCORD, ADVANCE, and VA diabetes trials: a position statement of the American Diabetes Association and a scientific statement of the American College of Cardiology Foundation and the American Heart Association. Diabetes Care 2009;32:187-192
16. Duckworth W, Abraira C, Moritz T, et al. Glucose control and vascular complications in veterans with type 2 diabetes. New Engl J Med 2009;360:129-139
17. Holman RR, Thorne KI, Farmer AJ, et al. Addition of biphasic, prandial, or basal insulin to oral therapy in type 2 diabetes. N Engl J Med 2007;357:1716-1730 (Pubitemid 350005153)
18. Finfer S, Chittock DR, Su SY, et al. Intensive versus conventional glucose control in critically ill patients. N Engl J Med 2009; 360:1283-1297
19. Currie CJ, Peters JR, Tynan A, et al. Survival as a function of HbA1c in people with type 2 diabetes: a retrospective cohort. Lancet 2010;375:481-489
20. Yki-Jarvinen H, Kauppila M, Kujansuu E, et al. Comparison of insulin regimens in patients with non-insulin-dependent diabetes mellitus. N Engl J Med 1992;327:1426-1433
21. Yki-Jarvinen H, Ryysy L, Nikkila K, Tulokas T, Vanamo R, Heikkila M. Comparison of bedtime insulin regimens in patients with type 2 diabetes mellitus: a randomized, controlled trial. Ann Intern Med 1999;30:389-396 (Pubitemid 29111220)
22. Yki-Järvinen H. Combination therapies with insulin in type 2 diabetes. Diabetes Care 2001;24:758-767 (Pubitemid 32888861)
23. Riddle MC, Rosenstock J, Gerich J; Insulin Glargine 4002 Study Investigators. The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients. Diabetes Care 2003;26:3080-3086 (Pubitemid 37339502)
24. Riddle MC, Schneider J; Glimepiride Combination Group. Beginning insulin treatment of obese patients with evening 70/30 insulin plus glimepiride versus insulin alone. Diabetes Care 1998;21:1052-1057 (Pubitemid 28368507)
25. Henry RR, Gumbiner B, Ditzler T, Wallace P, Lyon R, Glauber HS. Intensive conventional insulin therapy for type II diabetes: metabolic effects during a 6-mo outpatient trial. Diabetes Care 1993;16:21-31 (Pubitemid 23013820)
26. Gerstein HC, Miller ME, Byington RP, et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008; 358:2545-2559 (Pubitemid 351831356)
27. Purnell JQ, Hokanson JE, Marcovina SM, Steffes MW, Cleary PA, Brunzell JD. Effect of excessive weight gain with intensive therapy of type 1 diabetes on lipid levels and blood pressure: results from the DCCT. JAMA 1998;280:140-146 (Pubitemid 28498385)
28. Thorn LM, Forsblom C, Fagerudd J, et al. Metabolic syndrome in type 1 diabetes: association with diabetic nephropathy and glycemic control (the FinnDiane study). Diabetes Care 2005;28:2019-2024 (Pubitemid 41060978)
29. Vigneri P, Frasca F, Sciacca L, Pandini G, Vigneri R. Diabetes and cancer. Endocr Relat Cancer 2009;16:1103-1123
30. Donadon V, Balbi M, Ghersetti M, et al. Antidiabetic therapy and increased risk of hepatocellular carcinoma in chronic liver disease. World J Gastroenterol 2009;15:2506-2511
31. Li D, Yeung SC, Hassan MM, Konopleva M, Abbruzzese JL. Antidiabetic therapies affect risk of pancreatic cancer. Gastroenterology 2009;137:482-488
32. Bowker SL, Majumdar SR, Veugelers P, Johnson JA. Increased cancer-related mortality for patients with type 2 diabetes who use sulfonylureas or insulin. Diabetes Care 2006;29:254-258 (Pubitemid 44106500)
33. Landman GWD, Kleefstra N, van Hateren KJJ, Groenier KH, Gans ROB, Bilo HJG. Metformin associated with lower cancer mortality in type 2 diabetes: ZODIAC-16. Diabetes Care 2010;33:322-326
34. Home PD, Pocock SJ, Beck-Nielsen H, et al. Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial. Lancet 2009;373:2125-2135
35. Yang X, Ko GTC, So WY, et al. Associations of hyperglycemia and insulin usage with the risk of cancer in type 2 diabetes: the Hong Kong diabetes registry. Diabetes 2010;59:1254-1260
36. Inzucchi SE, Masoudi FA, Wang Y, et al. Insulin-sensitizing antihyperglycemic drugs and mortality after acute myocardial infarction: insights from the National Heart Care Project. Diabetes Care 2005;28:1680-1689 (Pubitemid 40923078)
37. McGuire DK, Newby LK, Bhapkar MV, et al. Association of diabetes mellitus and glycemic control strategies with clinical outcomes after acute coronary syndromes. Am Heart J 2004;147:246-252 (Pubitemid 38176824)
38. Frye RL, August P, Brooks MM, et al. A randomized trial of therapies for type 2 diabetes and coronary artery disease. N Engl J Med 2009;360:2503-2515
39. Banerji MA, Chaiken RL, Lebovitz HE. Long-term normoglycemic remission in black newly diagnosed NIDDM subjects. Diabetes 1996;45:337-341 (Pubitemid 26069048)
40. McFarlane SI, Chaiken RL, Hirsch S, Harrington P, Lebovitz HE, Banerji MA. Near-normoglycaemic remission in African- Americans with type 2 diabetes mellitus is associated with recovery of beta cell function. Diabet Med 2001;18:10-16 (Pubitemid 32158102)
41. Weng J, Li Y, Xu W, et al. Effect of intensive insulin therapy on β-cell function and glycaemic control in patients with newly diagnosed type 2 diabetes: a multicentre randomised parallel-group trial. Lancet 2008;371:1753-1760 (Pubitemid 351697950)
42. Chen H-S, Wu T-E, Jap T-S, Hsiao L-C, Lee S-H, Lin H-D. Beneficial effects of insulin on glycemic control and b-cell function in newly diagnosed type 2 diabetes with severe hyperglycemia after short-term intensive insulin therapy. Diabetes Care 2008;31:1927-1932
43. Nauck MA, Duran S, Kim D, et al. A comparison of twice-daily exenatide and biphasic insulin aspart in patients with type 2 diabetes who were suboptimally controlled with sulfonylurea and metformin: a non-inferiority study. Diabetologia 2007;50:259-267
44. Heine RJ, Van Gaal LF, Johns D, Mihm MJ, Widel MH, Brodows RG; GWAA Study Group. Exenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes: a randomized trial. Ann Intern Med 2005;143:559-569
45. Yoon NM, Cavaghan MK, Brunelle RL, Roach P. Exenatide added to insulin therapy: a retrospective review of clinical practice over two years in an academic endocrinology outpatient setting. Clin Ther 2009;31:1511-1523